ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Senate Authorizes $30 Million For Childhood Cancer Clinical Trials Research.

July 18, 2008

Screening Concepts For Minority Women and Hispanics Approved

May 26, 1989

Cancer Center Lineup complete: 11 Renewals, Funding Continued for Three, Two Unfunded

September 28, 1990

White House Picks Harold Varmus For NCI

May 21, 2010

Cancer Trials Take 800 Days To Start On Average; NCI Vows Improvement.

April 11, 2008

Biostatisticians Write To Varmus Asking NCI To Investigate

July 23, 2010